{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:25:30Z","timestamp":1791595530470,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202003AC100010"],"award-info":[{"award-number":["202003AC100010"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202003AC100010"],"award-info":[{"award-number":["202003AC100010"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008871","name":"Yunnan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["202102AA100051"],"award-info":[{"award-number":["202102AA100051"]}],"id":[{"id":"10.13039\/501100008871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spring City Plan: the High-level Talent Promotion and Training Project of Kunming: This project funded by Kunming Science and Technology Bureau, Yunnan Province, China."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People living with chronic disease, particularly seniors (\u226560 years old), made up of most severe symptom and death cases among SARS-CoV-2 infected patients. However, they are lagging behind in the national COVID-19 vaccination campaign in China due to the uncertainty of vaccine safety and effectiveness. Safety and immunogenicity data of COVID-19 vaccines in people with underlying medical conditions are needed to address the vaccine hesitation in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included participants (\u226540 years old) who received two doses of CoronaVac inactivated vaccines (at a 3\u20135 week interval) and were healthy or had at least one of 6 common chronic diseases. The incidence of adverse events after vaccination was monitored. Vaccine immunogenicity was studied by determining neutralizing antibodies and SARS-CoV-2-specific T cell responses post vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here we show that chronic diseases are associated with a higher rate of mild fatigue following the first dose of CoronaVac. By day 14\u201328 post vaccination, the neutralizing antibody level shows no significant difference between disease groups and healthy controls, except for people with coronary artery disease (p\u2009=\u20090.0287) and chronic respiratory disease (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0416), who show moderate reductions. Such differences diminish by day 90 and 180. Most people show detectable SARS-CoV-2-specific T cell responses at day 90 and day 180 without significant differences between disease groups and healthy controls.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results highlight the comparable safety, immunogenicity and cellular immunity memory of CoronaVac in seniors and people living with chronic diseases. This data should reduce vaccine hesitancy in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s43856-022-00216-2","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T16:32:02Z","timestamp":1669393922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Retrospective study of the immunogenicity and safety of the CoronaVac SARS-CoV-2 vaccine in people with underlying medical conditions"],"prefix":"10.1038","volume":"2","author":[{"given":"Chunmei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfang","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianpei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanjing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zumi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-0324","authenticated-orcid":false,"given":"Yong-Tang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-506X","authenticated-orcid":false,"given":"Zijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Precise-CoVaccine study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xupu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshuai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yating","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muxian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhua","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuemiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyun","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangxu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"216_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int\/ (accessed March 25, 2022) (2022)."},{"key":"216_CR2","first-page":"8012","volume":"25","author":"SA Meo","year":"2021","unstructured":"Meo, S. A., Meo, A. S., Al-Jassir, F. F. & Klonoff, D. C. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur. Rev. Med. Pharmacol. Sci. 25, 8012\u20138018 (2021).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"216_CR3","doi-asserted-by":"crossref","unstructured":"Wang, L. et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv [Preprint] (2022).","DOI":"10.1101\/2021.12.30.21268495"},{"key":"216_CR4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/tmi.13752","volume":"27","author":"M-A Davies","year":"2022","unstructured":"Davies, M.-A. et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Trop. Med. Int. Health 27, 564\u2013573 (2022).","journal-title":"Trop. Med. Int. Health"},{"key":"216_CR5","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ijid.2021.04.074","volume":"107","author":"V Soriano","year":"2021","unstructured":"Soriano, V., de Mendoza, C., G\u00f3mez-Gallego, F., Corral, O. & Barreiro, P. Third wave of COVID-19 in Madrid, Spain. Int. J. Infect. Dis. 107, 212\u2013214 (2021).","journal-title":"Int. J. Infect. Dis."},{"key":"216_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/d41586-022-00884-z","volume":"604","author":"D Lewis","year":"2022","unstructured":"Lewis, D. Will Omicron finally overpower China\u2019s COVID defences? Nature 604, 17\u201318 (2022).","journal-title":"Nature"},{"key":"216_CR7","unstructured":"Centre for Health Protection of the Department of Health. Provisional Analysis of the First 6748 Reported Death Cases in the 5th Wave. https:\/\/www.covidvaccine.gov.hk\/pdf\/ (accessed March 25, 2022) (2022)."},{"key":"216_CR8","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","volume":"383","author":"EJ Anderson","year":"2020","unstructured":"Anderson, E. J. et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 383, 2427\u20132438 (2020).","journal-title":"N. Engl. J. Med."},{"key":"216_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","volume":"8","author":"E Barron","year":"2020","unstructured":"Barron, E. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 8, 813\u2013822 (2020).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"216_CR10","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.arr.2020.101205","volume":"65","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res. Rev. 65, 101205 (2021).","journal-title":"Ageing Res. Rev."},{"key":"216_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412\u20131423 (2021).","journal-title":"N. Engl. J. Med."},{"key":"216_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.12968\/bjon.2021.30.6.344","volume":"30","author":"C Gordon","year":"2021","unstructured":"Gordon, C., Porteous, D. & Unsworth, J. COVID-19 vaccines and vaccine administration. Br. J. Nurs. 30, 344\u2013349 (2021).","journal-title":"Br. J. Nurs."},{"key":"216_CR13","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2213-8587(20)30405-8","volume":"9","author":"SJ McGurnaghan","year":"2021","unstructured":"McGurnaghan, S. J. et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol. 9, 82\u201393 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"216_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","volume":"27","author":"JV Lazarus","year":"2021","unstructured":"Lazarus, J. V. et al. A global survey of potential acceptance of a COVID-19 vaccine. Nature Med. 27, 225\u2013228 (2021).","journal-title":"Nature Med."},{"key":"216_CR15","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/vaccines8030482","volume":"8","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines 8, 482 (2020).","journal-title":"Vaccines"},{"key":"216_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/vaccines9010062","volume":"9","author":"K Wang","year":"2021","unstructured":"Wang, K. et al. Change of willingness to accept COVID-19 vaccine and reasons of vaccine hesitancy of working people at different waves of local epidemic in Hong Kong, China: repeated cross-sectional surveys. Vaccines 9, 62 (2021).","journal-title":"Vaccines"},{"key":"216_CR17","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/S2665-9913(21)00327-1","volume":"4","author":"NE Aikawa","year":"2022","unstructured":"Aikawa, N. E. et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. Lancet Rheumatol. 4, e113\u2013e124 (2022).","journal-title":"Lancet Rheumatol."},{"key":"216_CR18","doi-asserted-by":"crossref","unstructured":"Ali, H. et al. Robust antibody levels in both diabetic and non-diabetic individuals after BNT162b2 mRNA COVID-19 vaccination. Front. Immunol. 12, 752233 (2021).","DOI":"10.3389\/fimmu.2021.752233"},{"key":"216_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10408363.2022.2038539","volume":"59","author":"KI Notarte","year":"2022","unstructured":"Notarte, K. I. et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit. Rev. Clin. Lab. Sci. 59, 1\u201318 (2022).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"216_CR20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3390\/vaccines10030382","volume":"10","author":"E Papadokostaki","year":"2022","unstructured":"Papadokostaki, E. et al. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in people with diabetes: a prospective observational study. Vaccines 10, 382 (2022).","journal-title":"Vaccines"},{"key":"216_CR21","doi-asserted-by":"publisher","first-page":"nwac066","DOI":"10.1093\/nsr\/nwac066","volume":"9","author":"T Zhou","year":"2022","unstructured":"Zhou, T. et al. A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination. Natl Sci. Rev. 9, nwac066 (2022).","journal-title":"Natl Sci. Rev."},{"key":"216_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.mayocp.2020.12.024","volume":"96","author":"LJ Finney Rutten","year":"2021","unstructured":"Finney Rutten, L. J. et al. Evidence-based strategies for clinical organizations to address COVID-19 vaccine hesitancy. Mayo Clin. Proc. 96, 699\u2013707 (2021).","journal-title":"Mayo Clin. Proc."},{"key":"216_CR23","doi-asserted-by":"publisher","first-page":"e2021726118","DOI":"10.1073\/pnas.2021726118","volume":"118","author":"RM Kaplan","year":"2021","unstructured":"Kaplan, R. M. & Milstein, A. Influence of a COVID-19 vaccine\u2019s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci USA 118, e2021726118 (2021).","journal-title":"Proc Natl Acad Sci USA"},{"key":"216_CR24","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Med. 27, 1205\u20131211 (2021).","journal-title":"Nature Med."},{"key":"216_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"216_CR26","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","volume":"10","author":"A Jara","year":"2022","unstructured":"Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob. Health 10, e798\u2013e806 (2022).","journal-title":"Lancet Glob. Health"},{"key":"216_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3947\/ic.2021.0302","volume":"53","author":"WS Choi","year":"2021","unstructured":"Choi, W. S. & Cheong, H. J. COVID-19 vaccination for people with comorbidities. Infect. Chemother. 53, 155\u2013158 (2021).","journal-title":"Infect. Chemother."},{"key":"216_CR28","doi-asserted-by":"crossref","unstructured":"FDA. Vaccines and related biological products advisory committee meeting. December 10, 2020. FDA briefing document. Pfizer-BioNTech COVID-19 Vaccine. https:\/\/www.fda.gov\/media\/144245\/download (2020).","DOI":"10.47287\/cen-09931-buscon1"},{"key":"216_CR29","unstructured":"FDA. Vaccines and related biological products advisory committee meeting. December 17, 2020. FDA briefing document. Moderna COVID-19 Vaccine. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/vaccines-and-related-biological-products-advisory-committee-december-17-2020-meeting-announcement#event-information (2020)."},{"key":"216_CR30","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","volume":"22","author":"ME McMenamin","year":"2022","unstructured":"McMenamin, M. E. et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect. Dis. 22, 1435\u20131443 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"216_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.kint.2022.07.018","volume":"102","author":"FWT Cheng","year":"2022","unstructured":"Cheng, F. W. T. et al. The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases. Kidney Int. 102, 922\u2013925 (2022).","journal-title":"Kidney Int."},{"key":"216_CR32","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1016\/j.jinf.2022.08.008","volume":"85","author":"EYF Wan","year":"2022","unstructured":"Wan, E. Y. F. et al. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study. J. Infect. 85, e140\u2013e144 (2022).","journal-title":"J. Infect."},{"key":"216_CR33","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/S2352-3018(22)00033-9","volume":"9","author":"LC Netto","year":"2022","unstructured":"Netto, L. C. et al. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study. Lancet HIV 9, e323\u2013e331 (2022).","journal-title":"Lancet HIV"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00216-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00216-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T17:04:12Z","timestamp":1669395852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-022-00216-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["216"],"URL":"https:\/\/doi.org\/10.1038\/s43856-022-00216-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1794955\/v1","asserted-by":"object"}]},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,25]]},"assertion":[{"value":"4 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Z.Z. declares no competing non-financial interests but the following competing financial interests: this study is sponsored by Sinovac Biotech Ltd. Z.Z. on behalf of Yunnan University as an investigator has received research funding for this study from Sinovac Biotech Ltd. Gang Zeng declares competing non-financial interests as an employee of Sinovac Biotech Ltd. Other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}